An exploratory pharmacoscintigraphic single centre, open-label, crossover Phase 1b trial assessing CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinsons disease
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Paralysis
- Focus Pharmacokinetics
- 16 Jan 2025 New trial record
- 28 Nov 2024 According to Contera Pharma media release, first subject had been dosed in this trial